ARA-290

What is ARA-290?

ARA-290 represents molecular refinement of erythropoietin's tissue-protective properties. While full-length EPO stimulates red blood cell production through the classical EPO receptor, it also activates a distinct receptor complex called the innate repair receptor (IRR or tissue-protective receptor)—a heteromeric complex that triggers cell protection, reduces inflammation, and promotes tissue repair. ARA-290, an 11-amino acid EPO-derived peptide, selectively activates the IRR without engaging the erythropoietic EPO receptor.

This separation of functions enables clean investigation of EPO's tissue-protective mechanisms without the confounding hematological effects. Research has demonstrated ARA-290's effects in neuropathy models, ischemia-reperfusion injury, and inflammatory conditions—all mediated through IRR signaling pathways distinct from classical EPO effects. The peptide provides a unique tool for studying tissue protection mechanisms and innate repair receptor biology.

Mechanism of Action

ARA-290 functions through selective activation of the innate repair receptor (IRR), also called the tissue-protective receptor or β-common receptor (βcR). This receptor is a heteromeric complex composed of the erythropoietin receptor (EPOR) homodimer associated with CD131 (β-common receptor, shared with GM-CSF, IL-3, and IL-5 receptors). While full-length EPO activates both the classical EPOR homodimer (driving erythropoiesis) and the EPOR/CD131 heteromer (tissue protection), ARA-290 selectively activates only the EPOR/CD131 complex. This separation of functions enables clean study of EPO's tissue-protective mechanisms without hematological confounding.

Upon IRR activation, ARA-290 triggers JAK2/STAT3 and PI3K/Akt signaling cascades distinct from erythropoietic EPOR signaling. These pathways activate anti-apoptotic proteins (Bcl-xL, Bcl-2), reduce pro-inflammatory cytokines (TNF-α, IL-6), and enhance antioxidant defenses. The peptide demonstrates particular efficacy in neuronal tissues, reducing peripheral neuropathy in diabetes models and showing neuroprotective effects in ischemia. ARA-290 also modulates immune responses, reducing inflammation without immunosuppression—shifting macrophages toward M2 (anti-inflammatory) phenotype and enhancing regulatory T-cell function. This multi-system tissue protection makes ARA-290 valuable for studying innate repair mechanisms and EPO receptor biology beyond erythropoiesis.

Key Research Findings

• Reduces neuropathic pain by 45% in diabetic neuropathy models without affecting hematocrit or erythropoietin levels [Brines et al., 2008]
• Demonstrates selective EPOR/CD131 activation (EC50 1.8 nM) with no activity at EPOR homodimer [Brines et al., 2004]
• Reduces infarct size by 38% in myocardial ischemia-reperfusion injury through anti-apoptotic signaling [Brines & Cerami, 2012]
• Shows 60% reduction in TNF-α and 52% reduction in IL-6 in LPS-challenged macrophages [Brines et al., 2008]
• Improves corneal nerve fiber density by 32% in patients with sarcoidosis-associated small fiber neuropathy [Dahan et al., 2013]

Research Applications

• Innate repair receptor signaling
• Tissue protection mechanisms
• EPO receptor biology
• Neuroprotection studies
• Anti-inflammatory pathways
• Ischemia-reperfusion injury models
• Diabetic neuropathy research

Reconstitution & Use

Reconstitute with bacteriostatic water for laboratory use. For detailed reconstitution instructions and concentration ratios for your specific research application, see our reconstitution guide.

Storage & Handling

Store lyophilized at -20°C. Upon reconstitution with bacteriostatic water, maintain at 2-8°C and use within 30 days. This peptide demonstrates good stability in solution.